Global Partnerships Santen actively pursues international distribution and co-promotion agreements, recently partnering with AbbVie in China for glaucoma drops and with Novartis Korea. These moves show openness to strategic alliances and regional market access. With leadership in Japan and a presence in over 60 countries, there is significant potential to expand through similar partnerships or licensing deals in other high-growth ophthalmology markets.

Diverse Portfolio Santen maintains a diversified ophthalmology portfolio across prescription medicines, OTC products, and medical devices, plus ongoing licensing and product launches such as RC28-E and TAPCOM in China. This breadth creates multiple entry points for partnerships, including co-development, regional distribution, and access to innovative biologic ocular therapies.

Asia Expansion Recent activity centers on Asia: AbbVie China distribution, Novartis Korea promotion, and TAPCOM launch in China. This pattern indicates strong traction in East Asia and an opportunity to replicate successful models in neighboring markets with local regulatory and reimbursement support.

Tech Enablement Santen's IT and security stack including architecture, security certifications, cloud services, and analytics supports scalable digital marketing and partner ecosystems. This enables efficient joint marketing platforms, data-driven sales targeting, and secure collaboration with distributors and contract partners in new markets.

Market Credibility As Japan's market leader in prescription ophthalmic pharmaceuticals with a long history and a sizeable workforce, Santen offers credibility to potential partners and distributors. This positioning, combined with its international footprint, supports pursuing strategic alliances, licensing deals, and expansion into underpenetrated ophthalmology segments.